<DOC>
	<DOCNO>NCT01308229</DOCNO>
	<brief_summary>The purpose trial ass safety efficacy Nile PAX® Drug Eluting Coronary Bifurcation Stent System treatment single de novo bifurcation lesion native coronary artery main branch reference vessel diameter 2.5-3.5 mm side branch reference vessel diameter 2.0-3.0 mm .</brief_summary>
	<brief_title>Safety Efficacy Study Nile PAX Drug-Eluting Coronary Bifurcation Stent</brief_title>
	<detailed_description>The BIPAX clinical trial prospective , non-randomized , multicenter , clinical trial evaluate investigational coronary bifurcation device Nile PAX® patient main branch reference vessel diameter &gt; = 2.5 mm &lt; = 3.5 mm , side branch reference vessel diameter &gt; = 2.0 &lt; = 3.0 lesion length &lt; = 14 mm . The trial allow treatment single de novo bifurcation lesion native coronary artery follow provisional T-stenting technique mandatory pre-dilatation main branch . In case side branch require stent treatment complete possible Delta PAX® Drug Eluting Side Branch Stent . The BIPAX clinical trial enroll 100 patient . All patient receive Quantitative Coronary Angiography ( QCA ) stent implantation 9 month follow-up . All patient clinical follow-up 1 , 6 , 9 12 month subsequently every year 5 year .</detailed_description>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>De novo bifurcation lesion follow Medina classification except ( 0,0,1 ) . Maximum one bifurcation lesion per patient . Single bifurcation lesion per vessel . The patient least 18 year age . The patient clinical evidence ischemic heart disease , stable unstable angina , silent ischemia , positive functional trial . The patient acceptable candidate percutaneous transluminal coronary angioplasty ( PTCA ) , stenting , emergent coronary artery bypass graft ( CABG ) surgery . The patient patient 's legal representative inform nature trial agrees provision provide write informed consent approve Institutional Review Board/Ethics Committee ( IRB/EC ) respective clinical site . The patient agree return research facility require postprocedure followup visit . De novo bifurcation lesion Medina ( 0,0,1 ) . Left main bifurcation . Heavily calcify lesion . Severe tortuous lesion . Documented leave ventricular ejection fraction ( LVEF ) &lt; 30 % recent evaluation . Women childbearing potential . Chronic total occlusion ( CTO ) . Previous PCI target lesion . Second lesion require treatment target vessel . Second bifurcation lesion require treatment . Currently participate investigational drug another device trial complete primary endpoint clinically interfere current trial endpoint ; require coronary angiography , IVUS coronary artery imaging procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Bifurcation</keyword>
	<keyword>Dedicated</keyword>
	<keyword>Drug-eluting stent</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Coronary artery stenosis</keyword>
</DOC>